The Journal of clinical endocrinology and metabolism · 2025
Clomiphene Citrate Medication for Infertility and Risk of Stillbirth or Neonatal Death: A Population-based Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moore Vivienne, Rumbold Alice, Fernandez Renae, McElroy Heather, Moore Lynette, Giles Lynne, Grzeskowiak Luke, Roughead Elizabeth, Stark Michael, Russell Darryl, Davies Michael
Аннотация
OBJECTIVE: To assess associations between clomiphene citrate (CC) use and perinatal death.
DESIGN: Whole of population data linkage cohort.
SETTING: South Australia.
PARTICIPANTS: All women giving birth between July 2003 and December 2015 (n = 242,077).
METHODS: All births of at least 20 weeks were linked to government records of dispensed medications. A pregnancy was considered exposed to CC if a prescription was dispensed from 90 days before through to the end of a conception window. Descriptive statistics for stillbirths and neonatal deaths were stratified by multiplicity. For singletons, multivariable logistic regression models were used to examine the association of CC exposure with the combined outcome of perinatal death.
MAIN OUTCOME MEASURES: Stillbirths and neonatal deaths (with 28 days of birth) combined as perinatal deaths.
RESULTS: Among singletons, the prevalence of stillbirth was 6.6 per 1000 births, with neonatal deaths of 2.1 per 1000 live births. Among singletons conceived with CC, stillbirth and neonatal death had a prevalence of 10.2 and 3.1 per 1000, respectively. For the combined outcome of perinatal death, the odds ratio was 1.54 (95% confidence interval 1.15, 2.07), stable upon adjustment for factors conveying biological (eg, obesity, pregestational diabetes) and social (eg, disadvantage) risks for perinatal death.
CONCLUSION: Risk of perinatal death may be increased in pregnancies that follow use of CC. While established confounding factors related to infertility were taken into account, there may be some residual contribution of underlying infertility.
DESIGN: Whole of population data linkage cohort.
SETTING: South Australia.
PARTICIPANTS: All women giving birth between July 2003 and December 2015 (n = 242,077).
METHODS: All births of at least 20 weeks were linked to government records of dispensed medications. A pregnancy was considered exposed to CC if a prescription was dispensed from 90 days before through to the end of a conception window. Descriptive statistics for stillbirths and neonatal deaths were stratified by multiplicity. For singletons, multivariable logistic regression models were used to examine the association of CC exposure with the combined outcome of perinatal death.
MAIN OUTCOME MEASURES: Stillbirths and neonatal deaths (with 28 days of birth) combined as perinatal deaths.
RESULTS: Among singletons, the prevalence of stillbirth was 6.6 per 1000 births, with neonatal deaths of 2.1 per 1000 live births. Among singletons conceived with CC, stillbirth and neonatal death had a prevalence of 10.2 and 3.1 per 1000, respectively. For the combined outcome of perinatal death, the odds ratio was 1.54 (95% confidence interval 1.15, 2.07), stable upon adjustment for factors conveying biological (eg, obesity, pregestational diabetes) and social (eg, disadvantage) risks for perinatal death.
CONCLUSION: Risk of perinatal death may be increased in pregnancies that follow use of CC. While established confounding factors related to infertility were taken into account, there may be some residual contribution of underlying infertility.